Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Mitigation of arsenic-induced acquired cancer phenotype in prostate cancer stem cells by miR-143 restoration.

Ngalame NN, Makia NL, Waalkes MP, Tokar EJ.

Toxicol Appl Pharmacol. 2016 Dec 1;312:11-18. doi: 10.1016/j.taap.2015.12.013. Epub 2015 Dec 22.

2.

CYP2C8 Is a Novel Target of Peroxisome Proliferator-Activated Receptor α in Human Liver.

Makia NL, Goldstein JA.

Mol Pharmacol. 2016 Jan;89(1):154-64. doi: 10.1124/mol.115.100255. Epub 2015 Oct 14.

3.

Chronic inorganic arsenic exposure in vitro induces a cancer cell phenotype in human peripheral lung epithelial cells.

Person RJ, Ngalame NN, Makia NL, Bell MW, Waalkes MP, Tokar EJ.

Toxicol Appl Pharmacol. 2015 Jul 1;286(1):36-43. doi: 10.1016/j.taap.2015.03.014. Epub 2015 Mar 21.

4.

Regulation of human CYP2C9 expression by electrophilic stress involves activator protein 1 activation and DNA looping.

Makia NL, Surapureddi S, Monostory K, Prough RA, Goldstein JA.

Mol Pharmacol. 2014 Aug;86(2):125-37. doi: 10.1124/mol.114.092585. Epub 2014 May 15.

5.

Activator protein-1 regulation of murine aldehyde dehydrogenase 1a1.

Makia NL, Amunom I, Falkner KC, Conklin DJ, Surapureddi S, Goldstein JA, Prough RA.

Mol Pharmacol. 2012 Oct;82(4):601-13. Epub 2012 Jun 26.

6.

Murine hepatic aldehyde dehydrogenase 1a1 is a major contributor to oxidation of aldehydes formed by lipid peroxidation.

Makia NL, Bojang P, Falkner KC, Conklin DJ, Prough RA.

Chem Biol Interact. 2011 May 30;191(1-3):278-87. doi: 10.1016/j.cbi.2011.01.013. Epub 2011 Jan 20.

Supplemental Content

Loading ...
Support Center